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August 16, 2005:730–42ollowing ASD closure, plasma atrial natriuretic peptide levels
ould decrease (3). 4) Lateralization of headaches is a character-
stic feature of migraine (4). With the concept of paradoxical
mbolization of gas, thrombi, or vasoactive neuromediators (2),
hese potential precipitants are presumed to be streamed regularly
ver decades to the same brain parenchymal site or circulatory
egment in order to produce lateralizing headache (5). This is
ighly unlikely as paradoxical emboli are generally directed ran-
omly. 5) Atenolol—a first-line migraine prophylactic—does not
eadily cross the blood-brain barrier (BBB) or significantly influ-
nce either brain neuronal function or circulation (4). 6) Drugs
sed to manage patients with migraine aura such as nifedipine,
urosemide, and verapamil do not readily cross the intact BBB (6).
hese pharmacological absolutes challenge prevalent concepts of
rimary involvement of brain in migraine. 7) For a disease that can
ontinue for decades, a follow-up period of 12 months (1) is rather
hort.
An explanation is required for the characteristic late appearance
in the teens or twenties) or disappearance (second and third
rimesters of pregnancy and in later decades), in general, of
igraine despite continued presence of PFO/ASD. Second, a high
ncidence of right-to-left shunt has been seen in cluster headache
atients (42.5%, 17 of 40) (7). Cluster headache is a strictly
ateralized primary headache; brain ischemia is not implicated in its
athogenesis. Third, migraine-with-aura patients seem to respond
ar better than migraine-without-aura patients (1). Headaches are
ess frequent, less severe, and shorter in migraine-with-aura pa-
ients. When the frequency of headache attacks is lessened, the
ossibility of the placebo effect in migraine trials is greater (5).
At this juncture, it is necessary to weigh carefully whether we
eed more reflection about the basic issues surrounding the
pparent link between migraines and PFO/ASD or more clinical
rials.
Vinod Kumar Gupta, MD
Dubai Police Medical Services
.O. Box 12005
ubai
nited Arab Emirates
-mail: docgupta@emirates.net.ae
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he letter to the editor by Dr. Gupta raises some concerns, and it
uestions the validity of our hypothesis, which attempts to explain the
bserved connection between interatrial shunts and migraine head-
ches (1). It is appropriate to be skeptical of any new proposition,
specially one that “rocks the boat” of currently accepted beliefs. We
ubmit that there are enough independent observations of an associ-
tion between patent foramen ovale (PFO) closure and significant
eduction in migraine headache to allow this proposal a chance by
erforming a randomized clinical trial.
The clinical observation has been made that patients who have
n interatrial communication 1) have an increased incidence of
igraine headaches, and 2) closure of the interatrial communica-
ion results in significant improvement of the migraines. Although
hese studies are limited by their retrospective nature and a cohort
hat may not be reflective of the overall population of patients with
igraine headache, the compelling findings of these studies have
aised the possibility that closure of interatrial communications
ight provide a substantive treatment for migraine headaches.
Our hypothesis is that migraine headaches occur in people with
susceptible neuronal substrate. Several types of triggers might
nduce a migraine, but some of them may be chemically mediated,
ither through ingestion, or endogenously produced. Passing
hrough the venous system, these chemicals are usually detoxified
r perhaps just diluted in a first passage through the lungs.
owever, if a PFO or atrial septal defect (ASD) is present, then
he intermittent right-to-left shunt that occurs with straining in
ither entity may permit these chemicals to enter the cerebral
irculation in a high concentration and trigger the neurologic
onstellation that is recognized as a migraine headache. We agree
ith Dr. Gupta that emboli are unlikely to be the trigger of
igraine headaches.
This hypothesis does not explain the mechanism of all migraine
eadaches. We do not understand why patients who have migraine
ith aura respond more frequently to PFO closure than do patients
ho have migraine without aura. These fascinating observations
ay open more avenues for research that might produce more
uccessful therapeutic options for migraine sufferers than do
urrent medical regimens.
With 12% of the population suffering from migraine headaches,
e understand why the observations of reduction in migraine
eadaches following closure of interatrial shunts may generate
nterest and controversy. As with any new theory, the observations
hat support the theory come long before the randomized con-
rolled trial that will test its validity. Our study supports the
bservations from other independent centers and provides a
heoretical construct that “connects the dots” of rather disparate
ieces of data. Let us turn the question around. How does one
xplain these independent observations of decreased headache
ollowing PFO closure? Placebo? This is unlikely when five
ndependent centers all describe similar observations. Of the
atients with migraine and aura, 75% had complete resolution of
heir headaches, with some patients followed up to three years.
here is no drug or placebo that reports such a dramatic and
ong-lasting benefit to reduce migraine pain.
Finally, there are valid concerns with implanting a permanent
evice in someone’s heart, especially when the indication is not
ife-threatening. We should use the observations of the studies as
starting point to generate a hypothesis and then perform aandomized clinical trial that will assess the potential benefits and
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August 16, 2005:730–42isks of this technique. This is the classic scientific paradigm: if the
urrent theory does not fit the data, then revise the theory; do not
iscount reproducible data. The strength and consistency of the
bservations are compelling enough to give this randomized
linical trial a chance.
Jonathan Tobis, MD
abak Azarbal, MD
Adult Cardiac Catheterization Laboratory
avid Geffen School of Medicine
L-394 CHS
niversity of California at Los Angeles
0833 LeConte Avenue
os Angeles, CA 90095-1717
-mail: Jtobis@mednet.ucla.edu
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atheter Ablation After Mitral Replacement
ang et al. (1) report their experience of transcatheter ablation of
trial fibrillation (AF) in patients with mitral valve prostheses
MVP). The investigators claim that patients in both groups were
t the extreme end of the spectrum of atrial disease. However,
ore patients (a total of 14) had paroxysmal AF than did those
ith chronic AF; this does not necessarily constitute the extreme
nd of the disease. Did the researchers note any significant
ifferences in the incidences of AF recurrences between those who
ad paroxysmal and those who had chronic AF?
Lang et al. (1) conclude that the outcomes are similar to those
f standard patients undergoing catheter ablation, yet the 73%
75% in controls) sinus conversion rate falls far short of the results
chieved by current surgical techniques. The need for subsequent
ntervention for atrial tachycardia (AT) and recurrent AF was
retty high. Given that AF circuits are unstable, what was the
ncidence of peri-procedural AF in these patients?
Moreover, the lines of ablation varied within as well as between
he groups. Was this variation based on the findings of mapping?
t would have been interesting to know what the findings of the
apping were in terms of the sites of the triggers. Given that the
ines of ablation were different in these patients, how did the
nvestigators compare the incidences of AF recurrence and AT
etween the two groups?
Although most studies have concentrated on the conversion to
inus rhythm, AT is emerging as a troublesome complication of
ost forms of intervention. It is significant that the incidence of
T was 29% in the MVP group, particularly considering that all
atients in this group had specific lines of ablation to preclude AT!
Surgical scarring as a cause of AT in these patients is not a
enable explanation as none of them had preablation AT. It is
ore likely to be a consequence of the inability to create an
dequate block at the mitral isthmus owing to the fear of damaging
he prosthesis. It is well recognized that the creation of incomplete
ines of block will facilitate macro-reentrant arrhythmias. This rate
f sinus conversion and prevention of AT is then contingent on
ur ability to close the mitral isthmus adequately within these patients, without damaging the prosthesis. We clearly need to
efine the ablation technique to address this issue.
None of these patients had a preprocedural diagnosis of AT,
uggesting that AT was a consequence of the ablation. Are we then
erely replacing one arrhythmia with another? Evidently we need
o address this issue.
Notwithstanding these limitations, Lang et al. (1) are to be
ongratulated for achieving good results in a unique group of
atients who are difficult to treat. Ostensibly, the number of such
atients will be reduced in the future, as most of these patients will
ow have AF ablation, concomitant to mitral repair or replacement.
Ganesh Shanmugam, MS, MCh, FRCS
Department of Cardiothoracic Surgery
lasgow Royal Infirmary
lasgow
nited Kingdom
-mail: sgunpat@hotmail.com
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EPLY
e are thankful for the comments made by Dr. Shanmugam as we
an further emphasize major points already addressed in the
ethods and Discussion sections of our original study (1). Most of
ll, our goal was to establish for the first time the safety and
easibility of transcatheter ablation of atrial fibrillation (AF) in a
ery challenging group of patients with mitral valve prosthesis
MVP). We even performed a live satellite broadcast of such a
rocedure at the last Boston Atrial Fibrillation Symposium on
anuary 14, 2005, in a patient with MVP and chronic AF, where
e were able to cardiovert and maintain her into sinus rhythm
rom the end of the ablation until now.
In our study (1), patients with MVP had both paroxysmal AF
14 patients) and chronic AF (13 patients). Extreme end of the
trial disease was not merely based on the type of AF but on the
act that AF was highly symptomatic and refractory to at least two
ntiarrhythmic drugs in patients with very enlarged left atrium (55
m). Also, the 73% (75% in the control group) maintenance rate
f sinus rhythm was achieved by percutaneous transcatheter
blation in this selected group of patients. It is not rare to see AF
ccurrence within the first month following the ablation procedure
wing to tissue inflammation, and this does not generally influence
he outcomes. Some patients did not have additional lines done in
he left atrium as we were in the process of assessing the benefit of
hese lines, as already mentioned in the original report (1). This
as not due to variation in anatomic mapping. Furthermore, 81%
f patients in both groups had additional lines performed along the
itral isthmus and in the posterior wall; 12% of the MVP group
vs. 13% of the control group) had only the mitral isthmus line
one (again, as we were investigating the benefit of additional
ines; data now published [2]), allowing us to compare outcomes in
oth groups. Postablation left atrial tachycardia occurred in six
atients of the MVP group (one in the control group), probably to
